The ASCO Post: Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine

In addition to the new AACR award, Dr. Pazdur has received numerous awards and honors throughout his career: the Regulatory Affairs Professionals Society Patient-Centered Health Award (2021), the University of Chicago Cancer Research Foundation Simon M. Shubitz Cancer Prize and Lectureship (2020), the FDA Alumni Association Harvey W. Wiley Award (2019), recognition as one of OncLive’s Giants of Cancer Care (2019), the Reagan-Udall Foundation Innovations in Regulatory Science Award for Leadership (2018)...
Coverage

Daiichi Sankyo

By jpalfreyman on
Expanded Access Listings

Medical Access Program for Patritumab Deruxtecan

Conditions
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

The purpose of this Medical Access Program is to provide access to HER3-DXd for eligiblepatients with NSCLC who, in their treating physician's opinion, have an unmet clinicalneed which cannot be treated with approved and commercially available drugs and whocannot enter a clinical trial prior to commercial availability.

Subscribe to